Omeros again falls short in PhIII trial with drug for knee surgery patients

Omeros missed the main goal of a late-stage study of one of its lead product candidates in patients undergoing arthroscopic surgeries to remove damaged knee cartilage. The Seattle biotech ($OMER) broke the news late Thursday afternoon and its shares were off 5.31% to $5.53 at 9:40 a.m. ET Friday. Its study failed on the primary endpoint of a patient-reported symptoms score that includes knee...